Colorectal carcinoma (CRC) is the fourth commonest cancer in the western world and cancer of the uterine corpus, or endometrial carcinoma (EC), is the fourth commonest cancer among women. Both cause significant morbidity and mortality worldwide. There is evidence from rare, Mendelian cancer predisposition syndromes that CRC and EC can have a common aetiology. Specifically, germline mutations in mismatch repair (MMR) genes *MLH1*, *MSH2*, *MSH6* and *PMS2*[@b1], and in DNA polymerases *POLD1* and *POLE*[@b2] predispose to a high incidence (lifetime risk 30--71%[@b2][@b3][@b4][@b5]) of both CRC and EC. The MMR system maintains genomic stability by correcting mismatched nucleotide pairs that arise during DNA replication and MMR mutations cause a microsatellite instability (MSI+) phenotype in CRCs and ECs[@b6]. Bi-allelic *MLH1* promoter methylation[@b7][@b8] and a few somatic mutations in *MLH1* and *MSH2*[@b9] are seen in sporadic CRCs and ECs, causing the same MSI+ and hypermutator phenotype. Histologically, MMR-deficient CRCs and ECs are characterised by poor differentiation and the presence of mucinous and signet-cell features and tumour-infiltrating lymphocytes[@b10][@b11]. *POLE* and *POLD1* encode polymerases that synthesise respectively the leading and lagging strand of the DNA replication fork. The exonuclease (proofreading) domains of these polymerases increase replication fidelity by recognising and excising mispaired bases[@b12][@b13]. Germline missense mutations in the exonuclease domains of *POLD1* and *POLE* predispose to both CRC and EC, and somatic *POLE* mutations occur in sporadic CRCs and ECs[@b2][@b14][@b15][@b16]. Polymerase exonuclease domain mutations (EDMs) do not cause MSI, but lead to an ultramutator phenotype, with over one million base substitutions in some cancers.

Genome-wide association studies (GWAS) have successfully identified tens of common single nucleotide polymorphisms (SNPs) associated with a modestly increased risk (typically 10--25%) of CRC. In addition, one EC SNP, near *HNF1B*, has been reported at stringent levels of statistical significance. To date, the lists of CRC and EC SNPs are non-overlapping. Since CRC and EC may share mechanisms of pathogenesis, as evidenced by the high-penetrance germline mutations and the somatic (epi)mutations discussed above, we hypothesised (i) that some CRC SNPs may predispose to EC, and *vice versa*, and (ii) that there exist unidentified SNPs that predispose to both CRC and EC. In this study, we tested these hypotheses using 16 different CRC and EC GWAS data sets, totalling 13,265 cancer cases and 40,245 cancer-free or population controls.

Methods
=======

GWAS data sets
--------------

Five CRC GWAS data sets genotyped on various Illumina tag-SNP arrays were available, comprising: (i) CORGI (UK1), (ii) Scotland 1, (iii) VICTOR/QUASAR2/BC58, (iv) CFR1 and (v) CFR2/CGEMS (total 5,725 cases and 6,671 controls)[@b17][@b18][@b19][@b20][@b21]. The VQ58, CORGI and Scotland 1 series were genotyped using Illumina Hap300, Hap240S, Hap370, Hap550 or Omni2.5M arrays. BC58 genotyping was performed as part of the WTCCC2 study on Hap1.2M-Duo Custom arrays. The CCFR samples were genotyped using Illumina Hap1M, Hap1M-Duo or Omni-express arrays. CGEMS samples (all controls) were genotyped using Illumina Hap300 and Hap240 or Hap550 arrays. Standard quality -control measures were applied as reported[@b17]. Moreover, any duplicate or cryptically related samples were excluded by pairwise identity by descent (IBD) analysis.

EC GWAS comprised: (i) NSECG, (ii) ANECS and (iii) SEARCH (total 2,212 cases and 6,725 controls)[@b22]. All samples were of European ancestry with the majority of samples from the UK, and others from USA and Australia. Standard quality control measures were performed for each GWAS, as described in the referenced publications, and details about each dataset are shown in [Table 1](#t1){ref-type="table"}. Some of the control datasets, including the Wellcome Trust Case Control Consortium 2 (WTCCC2)[@b23], have previously been used in both CRC and EC GWAS. We ensured that such controls were assigned proportionately to case data sets and were not used more than once ([Table 1](#t1){ref-type="table"}).

Principal component analysis (PCA) was conducted for all samples together, to ensure that all individuals were of European ancestry and we excluded all individuals who clustered outside the main centroid in pairwise plots of the first 4 PCs. The adequacy of case-control matching and possibility of differential genotyping of cases and controls was assessed using Q-Q plots of test statistics. λ~GC~ values for the CORGI, Scotland1, VQ58, CCFR1 and CCFR2 studies were 1.02, 1.01, 1.01, 1.02 and 1.03 respectively, and those for NSECG, ANECS and SEARCH were 1.02, 1.02 and 1.00 respectively.

EC targeted genotyping data sets
--------------------------------

A further 4,330 EC cases and 26,849 female controls were genotyped as part of the Endometrial Cancer Association Consortium (ECAC), with samples from seven countries: UK, USA, Belgium, Germany, Norway, Sweden and Australia. The controls were selected from healthy females participating in the Breast Cancer Association Consortium (BCAC) and Ovarian Cancer Association Consortium (OCAC) part of the iCOGS project and matched and analysed with cases in eight groups by geographical location (see [Table 1](#t1){ref-type="table"}). These samples were genotyped using a custom Illumina Infinium iSelect array with 211,155 SNPs designed by the COGS (Collaborative Oncological Gene-environment Study) initiative[@b24][@b25][@b26][@b27]. The SNPs on this array were chosen based on regions of interest from previous breast, prostate, ovarian and endometrial cancer studies, rather than on genome-wide coverage. We did not impute genotypes from the COGS studies, but included directly-genotyped SNPs in the discovery meta-analysis. These SNPs were not used for locus fine mapping.

Association study and meta-analysis
-----------------------------------

Whole-genome imputation using two reference panels (1000 Genomes 2012 release[@b28] and 196 high-coverage whole genome-sequenced UK individuals) was performed with IMPUTE2[@b29], yielding up to 6 million SNPs either typed or imputed with high quality (info score \>0.9). Case-control analysis for each GWAS data set was performed using frequentist tests with a logistic regression model using SNPTEST (v2.4)[@b30]. There was no evidence of systematic over-dispersion of the test statistic for any of the 16 studies (lambda~GC~ = 1.01--1.04 based on weakly correlated SNPs, r^2^ \< 0.2). Fixed-effects, inverse variance weighted meta-analysis was conducted for the 6 million well-imputed SNPs in the eight CRC and EC GWAS (8,935 cases, 13,396 controls) across the genome using GWAMA (v2.1)[@b31]. For the \~200,00 SNPs genotyped on the COGS array, the additional 4,330 EC cases and 26,849 controls from ECAC were included in a meta-analysis of 16 studies yielding a total of 13,265 cases and 40,245 controls for these loci. SNPs with globally significant CRC/EC associations (P~meta~ \< 5 × 10^−8^) were identified and the regions examined using standard fine mapping and annotation methods.

Previously reported CRC and EC SNPs
-----------------------------------

The effects of 25 previously published tag-SNPs that have been formally associated with CRC risk in GWAS were investigated in EC ([Table 2](#t2){ref-type="table"}). We additionally assessed two SNPs (near *TERT*[@b32] and *MTHFR*[@b33][@b34]) with convincing CRC associations from focussed studies. We estimated that our EC sample set provided 72% power to detect the effect of a typical CRC SNP (allele frequency = 0.25, per allele odds ratio = 1.1) at P = 0.05, and 23% power to detect a similar allele at P = 0.001, corresponding to a false discovery rate of q = 0.05 in our sample. Two EC SNPs from GWAS[@b22] were similarly investigated in CRC. All of these SNPs were either discovered or replicated in European populations and were genotyped directly or had near-perfect proxies on the Illumina GWAS arrays used; 13 of the SNPs were also present on the iCOGS arrays. Three EC SNPs in the *TERT-CLPTM1L* region[@b35] were not included in this analysis, owing to poor tagging on the GWAS arrays and hence sub-optimal imputation.

Genome-wide enrichment of susceptibility SNPs between CRC and EC
----------------------------------------------------------------

Beyond the 29 previously published associations, we investigated the presence of genome-wide enrichment for CRC and EC. After removing previous associations, we pruned the set of 6 million typed or well-imputed SNPs (*r*^*2*^ \< 0.1) to 246,896. Using several P value thresholds, we determined whether there was a tendency for the same SNPs to co-occur in the lists of putative CRC and EC SNPs, irrespective of direction of effect.

Results
=======

We initially investigated the 29 previously-identified CRC and EC polymorphisms ([Table 2](#t2){ref-type="table"}). One SNP, rs2736100, originally reported in CRC[@b32], was significantly associated with EC risk (OR: 0.93, 95% confidence interval (95% CI): 0.89-0.96, P = 0.000167) after correcting for multiple testing (P\<0.001). The risk allele for CRC \[A\] was protective in EC. rs2736100 lies in the intronic region of the telomerase reverse transcriptase *TERT.* It or highly correlated SNPs have previously been associated with the risk of multiple different cancer types, and we ourselves have previously found evidence that these *TERT* SNPs are associated with EC risk[@b35]. Two other CRC SNPs (rs6691170 and rs10936599) were nominally associated with EC risk (P \< 0.05). Interestingly, the latter of these lies close to the telomerase RNA component *TERC* locus; it is a multi-cancer risk SNP[@b36][@b37][@b38] and has been associated with longer telomeres. Overall, 15 of the 29 SNPs showed the same direction of effect in both cancer types (that is, same nominal risk allele, irrespective of effect size), and this evidently was not a significant deviation from randomness (P = 1, binomial sign test).

Meta-analysis of all CRC and EC data sets revealed a single genome-wide significant SNP, rs3184504, on chromosome 12q24 (OR: 1.10, 95% CI 1.07--1.13, P~meta~: 7.23 × 10^−9^, heterogeneity *I*^*2*^ = 0; [Fig. 1](#f1){ref-type="fig"}, [Supplementary Table 1](#S1){ref-type="supplementary-material"}). This SNP is a missense variant (p.Trp262Arg) in exon 4 of *SH2B3*. It has not previously been associated with either CRC or EC. The major \[C\] allele was consistently the risk allele in all datasets, including those analysed using the iCOGS array, on which the SNP was included due to promising, but unproven, associations below genome-wide significance in previous breast cancer and EC GWAS. An additional 3 SNPs ([Fig. 2](#f2){ref-type="fig"}) in strong pairwise linkage disequilibrium (LD) with rs3184504 (r^2^ \> 0.9) showed strong evidence of CRC-EC association (P~fine\ mapping~ \< 10^−5^). These 4 SNPs lie in a 68kb region, that includes the genes *SH2B3* and *ATXN2*, and their functional annotation is shown in [Supplementary Table 2](#S1){ref-type="supplementary-material"}. None of the 4 SNPs was associated with the mRNA level of *SH2B3*, *ATXN2* or other nearby genes in public eQTL databases (details not shown).

There are SNPs that have previously been independently identified in GWAS of different phenotypes where the risk allele for one phenotype is the protective allele for another[@b39][@b40]. In order to search for SNPs for which the same allele has differing directions of effect in CRC and EC, we conducted a fixed-effect meta-analysis with the odds ratios of all the CRC SNPs GWAS inverted ([Supplementary Table 3](#S1){ref-type="supplementary-material"}). In this analysis, we discovered rs12970291 on chromosome 18q22, where the major G allele is protective in CRC (OR:0.78, 95%CI:0.69-0.90, 3.42 × 10^−4^) and confers risk in EC (OR:1.24, 95%CI: 1.11--1.38, p:1.11 × 10^−4^). In meta-analysis, the rs12970291 association reached genome-wide significance (OR:1.26, 95%CI:1.16--1.38, P~meta~:4.82 × 10^−8^; [Fig. 3](#f3){ref-type="fig"}). Fine mapping analysis identified a large number of SNPs in high pairwise LD with rs12970291 (r^2^ \> 0.85), in a 70 kb region that includes the gene *TSHZ1*, which is \~15 kb proximal to rs12970291 ([Fig. 4](#f4){ref-type="fig"}). Seventeen SNPs had a stronger disease association than rs12970291 in fine mapping, with the lowest P value at rs35185115 (P~fine\ mapping~ = 1.08 × 10^−6^). Fine mapping of CRC and EC GWAS separately ([Supplementary Figure 1](#S1){ref-type="supplementary-material"}) showed an association peak occurring in the same LD block between 10.5--51.8 kb downstream of *TSHZ1*, while an additional suggestive association signal near rs17263435 (P~EC~ = 4.35 × 10^−5^) was not present in CRC (P~CRC~ = 0.1). Several SNPs in the region have potential functional importance ([Supplementary Table 4](#S1){ref-type="supplementary-material"}), and of particular note is the missense SNP rs3390274 (p.Ala468Thr) in the last exon of *TSHZ1*. SNPs with a pairwise LD of \>0.4 with rs12970291 in the region were not significantly associated with mRNA level of *TSHZ1* or other nearby genes in public eQTL databases (details not shown).

Finally, we performed genome-wide enrichment analysis for nearly 250,000 independent SNPs (*r*^*2*^ \< 0.1) below genome-wide significance levels to investigate whether there was a set of cryptic shared CRC and EC risk loci ([Supplementary Table 5](#S1){ref-type="supplementary-material"}). Using P value thresholds of 10^−3^, 10^−2^ and 0.05, we found no evidence of a significant sharing of CRC and EC SNPs using this method.

Discussion
==========

Using a combined CRC and EC GWAS meta-analysis, we have identified a region on chromosome 12q24.1 spanning two genes, *SH2B3* and *ATXN2*, which contains a SNP that is formally associated at GWAS thresholds of significance with cancer risk. Of the variants in this region, rs3184504 is of particular interest, because it is a non-synonymous change (TGG → CGG; p.Trp262Arg) in the pleckstrin homology domain of SH2B3, which is *a priori* a much stronger candidate than the spinocerebellar ataxia gene *ATXN2*. SH2B3 is a member of the SH2B adaptor family of proteins and is involved in a range of signalling activities by growth factor and cytokine receptors. It is a key negative regulator in cytokine signalling in haematopoiesis, and is expressed at a high level in the bone marrow and white blood cells, but at a low level in the normal bowel and endometrium (EMBL-EBI expression atlas). Comparative genomics shows that the rs3184504 risk allele (C, Arg residue) is conserved in all primates and some vertebrates ([Supplementary Figure 1](#S1){ref-type="supplementary-material"}), and has a much lower allele frequency (\~0.5) in Europeans than in African, Asian and admixed American populations (\~1.0). Amino acids Trp (tryptophan) and Arg (arginine) present in the two forms of the polymorphic SH2B3 protein possess a hydrophobic (uncharged) and positively charged side chain respectively. Different programs that predict the effect of this variation on protein function vary in their assessment (Grantham score = 121 (range 0--215)[@b41], Polyphen2 = 0.12[@b42], SIFT = 1.0[@b43], CADD score PHRED-scaled = 5.532[@b44]); overall, the possibility remains that the amino acid change has a modest or greater effect on protein function. The NHGRI GWAS Catalog shows that SNPs in the *SH2B3*/*ATNX2* region including rs3184504 and rs653178 have been previously associated with immune-mediated conditions: coeliac disease[@b45], rheumatoid arthritis[@b43], type 1 diabetes[@b46], autoimmune hepatitis[@b47] and also cardiovascular traits including coronary artery disease[@b48] and blood pressure[@b49]. The genotype at rs653178 has been linked to levels of *SH2B3* mRNA expression in peripheral blood cell eQTL analysis (p = 9.24 × 10^−12^), although this association is not present in public eQTL data sets. Interestingly, rs3184504 T is generally the risk allele in autoimmune traits, suggesting opposing effects of the functional polymorphism on cancer and other traits, perhaps *via* shared effects on immune activation. A similar phenomenon has been found for the *HNF1B* SNP rs4430796 which has opposing effects on EC and type 2 diabetes risk[@b50].

The *TERT*-*CLPTM1L* locus has been identified in multiple cancer susceptibility GWAS[@b51][@b52][@b53][@b54][@b55][@b56][@b57][@b58] and it is of interest that the CRC SNP rs2736100 also shows signs of significance in EC in our analysis (OR:1.08, 95%CI:1.04-1.12, P = 1.67 × 10^−4^). In parallel with this study and using overlapping data sets, we have recently performed a detailed analysis of the *TERT-CLPTM1L* locus in EC which provided evidence that rs7705526 is associated with EC risk (P~assoc~ = 7.7 × 10^−5^), albeit at locus-specific rather than genome-wide significance thresholds[@b35]. rs7705526 is moderately correlated with rs2736100 (r^2^ \~ 0.5) but is poorly tagged in most Illumina GWAS arrays. [Supplementary Figure 2](#S1){ref-type="supplementary-material"} shows the complex LD structure between these two SNPs and 4 other SNPs previously associated with CRC and EC at varying levels of significance (P = 8.4 × 10^−3^ to 4.9 × 10^−6^) at this locus.

The rs2736100 A allele is the risk allele for CRC and testicular germ cell tumour, while the same allele is protective for EC, glioma and lung cancer, suggesting that this variant has its effects in a tissue-specific manner. Interestingly, we have found evidence in this study for a SNP (rs12970291, chromosome 18q22) that has opposing allelic effects on CRC and EC risk. The top candidate gene in this region is *TSHZ1* which encodes zinc finger homeodomain factor teashirt zinc finger family member 1, a protein involved in skin, skeletal, brain and gut development[@b59] that is functionally related to the CRC gene *BMP4*[@b60]. One of several candidate SNPs near and within *TSHZ1* is the uncommon missense variant rs33930274 (p.Ala468Thr) in the last exon of *TSHZ1*, although the predicted functional consequences of this change are inconsistent (Grantham score = 58, SIFT = 0.0, Polyphen2 = 0.0, CADD score PHRED-scaled: 0.001).

Apart from the *SH2B3* and *TERT* SNPs, only two of 27 previously-reported CRC SNPs, including one near *TERC*, showed any good evidence of association with EC and neither of the known EC SNPs was associated with CRC risk. Otherwise, there was no convincing evidence for a shared EC and CRC predisposition based on common polymorphisms, although it will be important to keep repeating multi-cancer GWAS as more risk SNPs are identified, and sub-set analyses -- for example of MSI+ ECs and CRCs -- might also be fruitful. It remains a little puzzling that, like breast and ovarian cancer, CRC and EC share high-penetrance risk alleles, yet relatively few common risk alleles of modest effect.
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![Forest plot showing association between cancer risk and rs3184504 genotype in each data set.\
Studies are shown in order of EC GWAS, EC iCOGS and CRC GWAS ([Table 1](#t1){ref-type="table"}). Black squares represent the point estimate of the odds ratio and have areas proportional to study size. Lines represent 95% confidence intervals. The diamond shows the summary statistic. The overall heterogeneity statistic is shown. There is also no evidence of heterogeneity between the pooled CRC and pooled EC studies (details not shown).](srep17369-f1){#f1}

![Regional association plot for region around rs3184504.\
Plots are produced in LocusZoom and show the most strongly associated SNP, rs3184504 (purple diamond). rs7137828, intron of *ATXN2*, is the SNP with the second lowest P value. The primary aim of this analysis is to compare association signals among SNPs in the region. Therefore, the data are derived from a meta-analysis of genotyped or high-quality imputed SNPs in the GWAS data sets, and because imputation quality was more variable in iCOGS than in the GWAS data, the iCOGS samples are not included.](srep17369-f2){#f2}

![Forest plot showing association between cancer risk and rs12970291 genotype in each data set.\
Legend is as for [Fig. 1](#f1){ref-type="fig"}.](srep17369-f3){#f3}

![Regional association plot for region around rs12970291.\
Legend is as for [Fig. 2](#f2){ref-type="fig"}, except as follows. The most strongly associated SNP from the full discovery meta-analysis (rs12970291, purple diamond) is not the most strongly associated in the GWAS data sets. The most strongly associated SNP, rs35185115, lies about 30kb downstream of *TSHZ1*, but this SNP imputed poorly in iCOGS and was therefore assessed in fewer samples in the discovery meta-analysis than rs12970291, which was directly genotyped in iCOGS.](srep17369-f4){#f4}

###### Details of the CRC and EC studies used in this analysis.

                                                         Study                                                                   Case sampling frame                                                                           Control sampling fram                                                                Genotyping Platform                           Cases   Controls
  ---- ----------------- --------------------------------------------------------------------- ---------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- -------------------------------------------------------------------- ------- ----------
       CRC GWAS                                                                                                                                                                                                                                                                                                                                                          
  1    UK1-CORGI                   Colorectal Tumour Gene Identification Consortium                           England; Genetics clinic-based, with family history of CRC                 England; spouses and partners of cases with no personal or family history of colorectal neoplasia                            Illumina Hap550                              888      899
  2    Scotland1                                       Scotland                                                     Scotland; population based CRC cases, age \<55                                            Scotland; from NHS registers matched by age and region                                   Illumina HumanHap300 and Illumina HumanHap240S              973      998
  3    VQ                                           VICTOR/QUASAR2                              UK; CRC cases enrolled in chemotherapy clinical trials (NSAID and monoclonal antibody)                                                                                                       Illumina HumanHap300, Illumina HumanHap270, Illumina Human 1.2MDuo   1894      2674
       WTCCC2 BC58                               UK 1958 Birth Cohort                                                                                                                                       UK; population based controls, born within one week in 1958                                                Illumina 1.2M                                          
  4    CFR1                               Colon Cancer Family Registry Phase1                                      USA and Australia; cases from cancer registries                                        USA and Australia; population based controls, no family history                                             Illumina Human1M                            1175      999
  5    CFR2                              Colon Cancer Family Registry Phase 2                                      USA and Australia; cases from cancer registries                                                                                                                                                    Illumina Human1M                             795        
       CGEMS prostate             Cancer Genetic Markers of Susceptibility (Prostate)                                                                                                                     USA; population based cancer free controls from prostate study                                            Illumina HumanHap550                                    1101
       EC GWAS                                                                                                                                                                                                                                                                                                                                                           
  6    NSECG                         National Study of Endometrial Cancer Genetics                                            UK; population based cases                                                                                                                                                       Illumina660WQuads, HumanHap550                      925        
       CGEMS breast                Cancer Genetic Markers of Susceptibility (Breast)                                                                                                                       USA; population based cancer free controls from breast study                                             Illumina HumanHap550                                    1141
  7    ANECS                         Australian National Endometrial Cancer Study                                         Australia; population based cases                                                                                                                                                            Illumina 610K                               606        
       QIMR                            Queensland Institute of Medical Research                                                                                                                             Australia; parents of participants in adolescent twin study                                                Illumina 610K                                        1846
       HCS                                      Hunter Community Study                                                                                                                                                  Australia; population-based cohort                                                             Illumina 610K                                        1237
  8    SEARCH               UK Studies of Epidemiology and Risk factors in Cancer Heredity                 England; population based cases via cancer registries, age \<69                                                                                                                                             Illumina 610K                               681        
       WTCCC2 NBS                                                                                                                                                                                     UK; population based controls identified through National Blood Service                                          Illumina 1.2M                                        2501
       EC COGS                                                                                                                                                                                                                                                                                                                                                           
  9    ANECS                         Australian National Endometrial Cancer Study                                         Australia; population based cases                                                                                                                                                      Illumina Infinium iSelect                         373        
       NECS                               Newcastle Endometrial Cancer Study                                               Australia; hospital-based cases                                                                                                                                                       Illumina Infinium iSelect                         165        
       ABCFS                             Australian Breast Cancer Family Study                                                                                                                                            Australia; from electoral rolls                                                        Illumina Infinium iSelect                                  443
       AOCS                                 Australian Ovarian Cancer Study                                                                                                                                      Australia; population-based, from electoral rolls                                               Illumina Infinium iSelect                                  817
       MCCS                              Melbourne Collaborative Cohort Study                                                                                                                                      Australia; random sample from initial cohort                                                  Illumina Infinium iSelect                                  437
  10   SEARCH               UK Studies of Epidemiology and Risk factors in Cancer Heredity                                 England; population based cases                                                              England; population based controls                                                       Illumina Infinium iSelect                         773     7,510
  11   NSECG                         National Study of Endometrial Cancer Genetics                                         England; population based cases                                                                                                                                                       Illumina Infinium iSelect                         965        
       BBCS                                   British Breast Cancer Study                                                                                                                  UK; friend, sister-in-law, daughter-in-law or other non-blood relative of breast cancer case                          Illumina Infinium iSelect                                 1,353
       SBCS                                  Sheffield Breast Cancer Study                                                                                                                          UK; women attending Sheffield Mammography Screening, with no breast lesion                                   Illumina Infinium iSelect                                  835
       UKBGS                               UK Breakthrough Generations Study                                                                                                                                 UK; women without breast lesions selected from BGS cohort                                           Illumina Infinium iSelect                                  449
  12   MECS                                  Mayo Endometrial Cancer Study                                                    USA; Hospital based cases                                                                                                                                                          Illumina Infinium iSelect                         221        
       MCBCS                                Mayo Clinic Breast Cancer Study                                                                                                                              USA; Cancer-free women presenting for general medical examination                                       Illumina Infinium iSelect                                 1,762
       MCBCS/MCOCCCS                 Mayo Clinic Ovarian Cancer Case-Control Study                                                                                                                       USA; Cancer-free women presenting for general medical examination                                       Illumina Infinium iSelect                                  593
  13   LES                                  Leuven Endometrial Cancer Study                                                 Belgium; hospital based cases                                                                                                                                                        Illumina Infinium iSelect                         321        
       LMBC                             Leuven Multidisciplinary Breast Centre                                                                                                                                          Belgium; controls from blood donors                                                      Illumina Infinium iSelect                                 1,382
  14   BECS/HJECS                   Bavarian/Hannover-Jena Endometrial Cancer Study                                  Germany; population and hospital-based cases                                                                                                                                                Illumina Infinium iSelect                         137        
       BBCC                            Bavarian Breast Cancer Cases and Controls                                                                                                                            Germany; healthy women \>55yrs from newspaper advertisement                                          Illumina Infinium iSelect                                  441
       BSUCH                    Breast Cancer Study of the University Clinic Heidelberg                                                                                                                                    Germany; female blood donors                                                          Illumina Infinium iSelect                                  920
       ESTHER                                 ESTHER Breast Cancer Study                                                                                                                                        Germany; random sample from routine health check-up                                              Illumina Infinium iSelect                                  486
       GC-HBOC                 German Consortium for Hereditary Breast & Ovarian Cancer                                                                                                                                         Germany; KORA study                                                              Illumina Infinium iSelect                                  138
       GENICA                  Gene Environment Interaction and Breast Cancer in Germany                                                                                                                                  Germany; random address sample                                                         Illumina Infinium iSelect                                  420
       MARIE                          Mammary Carcinoma Risk Factor Investigation                                                                                                                               Germany; randomly drawn from population registries                                               Illumina Infinium iSelect                                 1,712
  15   MoMaTEC                   Molecular Markers in Treatment of Endometrial Cancer                                       Norway; population based cases                                                                                                                                                       Illumina Infinium iSelect                         599        
       NBCS                                  Norwegian Breast Cancer Study                                                                                                                                Norway; attendees at Norwegian Breast Cancer Screening Program                                         Illumina Infinium iSelect                                  234
  16   CAHRES/RENDOCAS                  Cancer Hormone Replacement Epidemiology                                             Sweden; population based cases                                                                                                                                                       Illumina Infinium iSelect                         543        
       RENDOCAS                        Registry of Endometrial Cancer in Sweden                                              Sweden; hospital based cases                                                                                                                                                        Illumina Infinium iSelect                         233        
       KARBAC                               Karolinska Breast Cancer Study                                                                                                                                                     Sweden; blood donors                                                              Illumina Infinium iSelect                                 6,917
       pKARMA             Karolinska Mammography Project for Risk Prediction of Breast Cancer                                                                                                                Sweden; cancer-free participants of mammography screening                                           Illumina Infinium iSelect                                 6,917

###### Association statistics for the known CRC SNPs tested in EC, and vice versa.

  Cancer GWAS        SNP       Chr   Position (build 37)       Nearby gene(s)        Minor Allele   MAF    P-value in other phenotype   OR (minor allele)   L95 CI   U95 CI   Same effect direction in CRC and EC?   iCOGS EC samples included?                                             Reference
  ------------- ------------- ----- --------------------- ------------------------- -------------- ------ ---------------------------- ------------------- -------- -------- -------------------------------------- ---------------------------- -----------------------------------------------------------------------------------------------
  CRC             rs1801133     1        11,856,378                 MTHFR                 A         0.34             0.686                    0.99           0.92     1.06                    Yes                                No                                          Hubner *et al.* Int Journal Cancer2006
  CRC            rs10911251     1        183,081,194                LAMC1                 C         0.43             0.236                    1.04           0.97     1.12                     No                                No                        Peters *et al.* Gastroenterology 2013, Whiffin *et al.* Hum Mol Genet 2014
  CRC             rs6691170     1        222,045,446               DUSP10                 T         0.37             0.023                    1.09           1.01     1.17                    Yes                                No                                              Houlston *et al.* Nat Gen 2010
  CRC            rs10936599     3        169,492,101                TERC                  T         0.24             0.033                    0.92           0.84     0.99                    Yes                                No                                              Houlston *et al.* Nat Gen 2010
  CRC             rs2736100     5         1,286,516                 TERT                  A         0.5           **0.000167**                0.93           0.89     0.96                     No                               Yes               Kinnersley Br J Cancer 2012, Rafnar *et al.* Nat Gen 2009 Peters *et al.* Human Genetics 2012
  CRC             rs647161      5        134,499,092                PITX1                 C         0.33             0.559                    1.02           0.95     1.1                      No                                No                              Jia *et al.* Nat Gen 2013, Whiffin *et al.* Hum Mol Genet 2014
  CRC             rs1321311     6        36,622,900                CDKN1A                 A         0.24             0.925                    1.00           0.92     1.08                     No                                No                                               Dunlop *et al.* Nat Gen 2012
  CRC            rs16892766     8        117,630,683                EIF3H                 C         0.09             0.134                    0.95           0.88     1.02                     No                               Yes                                              Tomlinson *et al.* Nat Gen 2008
  CRC             rs6983267     8        128,413,305                 MYC                  T         0.46             0.143                    1.03           0.99     1.07                     No                               Yes                                              Tomlinson *et al.* Nat Gen 2007
  CRC            rs10795668    10         8,701,219                 GATA3                 A         0.32             0.715                    0.99           0.92     1.06                    Yes                                No                                              Tomlinson *et al.* Nat Gen 2008
  CRC             rs1035209    10        101,345,366          NKX2-3, SLC25A28            T         0.2              0.243                    1.05           0.97     1.15                    Yes                                No                                            Whiffin *et al.* Hum Mol Genet 2014
  CRC             rs3824999    11        74,345,550                 POLD3                 T         0.49             0.647                    0.98           0.92     1.05                    Yes                                No                                               Dunlop *et al.* Nat Gen 2012
  CRC             rs3802842    11        111,171,709       COLCA1, COLCA2, POU2AF1        C         0.31             0.513                    0.99           0.94     1.03                     No                               Yes                                               Tenesa *et al.* Nat Gen 2008
  CRC            rs10774214    12         4,368,352                 CCND2                 T         0.38             0.171                    1.05           0.98     1.13                    Yes                               Yes                              Jia *et al.* Nat Gen 2013, Whiffin *et al.* Hum Mol Genet 2014
  CRC             rs3217810    12         4,388,271                 CCND2                 T         0.14             0.762                    1.02           0.92     1.13                    Yes                                No                        Peters *et al.* Gastroenterology 2013, Whiffin *et al.* Hum Mol Genet 2014
  CRC            rs11169552    12        51,155,663              DIP2B, ATF1              T         0.26             0.963                    1.00           0.93     1.08                     No                                No                                              Houlston *et al.* Nat Gen 2010
  CRC             rs4444235    14        54,410,919                 BMP4                  C         0.48              0.1                     1.03           0.99     1.07                    Yes                               Yes                                              Houlston *et al.* Nat Gen 2008
  CRC             rs1957636    14        54,560,018                 BMP4                  T         0.41             0.961                    1.00           0.96     1.04                     No                               Yes                                           Tomlinson *et al.* PLoS Genetics 2011
  CRC            rs16969681    15        32,993,111                 GREM1                 T         0.09             0.379                    0.97           0.90     1.04                     No                               Yes                                           Tomlinson *et al.* PLoS Genetics 2011
  CRC            rs11632715    15        33,004,247                 GREM1                 A         0.48             0.332                    1.04           0.97     1.11                    Yes                                No                                           Tomlinson *et al.* PLoS Genetics 2011
  CRC             rs9929218    16        68,820,946              CDH1, CDH3               A         0.29             0.679                    0.98           0.91     1.06                    Yes                                No                                              Houlston *et al.* Nat Gen 2008
  CRC             rs4939827    18        46,453,463                 SMAD7                 C         0.46             0.229                    0.98           0.94     1.02                    Yes                               Yes                                              Broderick *et al.* Nat Gen 2007
  CRC            rs10411210    19        33,532,300                 RHPN2                 T         0.09             0.202                    1.04           0.98     1.12                     No                               Yes                                              Houlston *et al.* Nat Gen 2008
  CRC             rs961253     20         6,404,281                 BMP2                  A         0.37             0.975                    1.00           0.96     1.04                     No                               Yes                                              Houlston *et al.* Nat Gen 2008
  CRC             rs4813802    20         6,699,595                 BMP2                  G         0.37             0.268                    1.04           0.97     1.12                    Yes                                No                                           Tomlinson *et al.* PLoS Genetics 2011
  CRC             rs2423279    20         7,812,350                 HAO1                  C         0.24             0.897                    1.01           0.93     1.09                    Yes                                No                              Jia *et al.* Nat Gen 2013, Whiffin *et al.* Hum Mol Genet 2014
  CRC             rs4925386    20        60,921,044                 LAMA5                 T         0.3              0.064                    1.07           1.00     1.16                     No                                No                            Houlston *et al.* Nat Gen 2010, Peters *et al.* Human Genetics 2012
  EC             rs749292\*    15        51,558,731                CYP19A1                A         0.46             0.066                    0.95           0.91     1.00                     No                               Yes                                               Spurdle *et al.* Nat Gen 2011
  EC             rs4430796\*   17        36,098,040                 HNF1B                 G         0.47             0.601                    0.99           0.94     1.04                    Yes                               Yes                                  Setiawan *et al.* Cancer Epidemiol Biomarkers Prev 2009

Chr = chromosome, OR = odds ratio, MAF = minor allele frequency, OR = odds ratio, L95 CI = lower 95% confidence interval odds ratio, U95 CI = upper 95% confidence interval odds ratio. The original studies providing the data are listed in [Supplementary Information](#S1){ref-type="supplementary-material"}.
